IRIDEX Corporation (Nasdaq:IRIX) announced today its collaboration with Bausch & Lomb to design and manufacture a green (532 nm) laser photocoagulator module, which will be incorporated into the Bausch & Lomb Millennium(TM) Microsurgical System.

Eyes were treated using either a MicroPulse subthreshold treatment protocol with the IRIDEX OcuLight SLx laser photocoagulator or the ETDRS photocoagulation protocol with an argon laser photocoagulator.

In 1970, we were the first company to introduce a laser in this field; since then, we have followed with a series of additional sight-preserving milestones, including the first laser photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator, photodynamic therapy laser, the revolutionary Selective Laser Trabeculoplasty (SLT) system and solid state multicolor laser.

In the retrospective clinical study, 57 eyes of 52 patients with subfoveal occult wet AMD were treated with IRIDEX' IRIS Medical(R) OcuLight(R) SLx 810 nm diode laser photocoagulator in its unique LongPulse(TM) operating mode using a TTT protocol and were followed for an average of 10 months.

The study included 229 eyes of 152 patients with dry AMD that were randomized to either receive a single treatment with the Company's IRIS Medical OcuLight SLx infrared laser photocoagulator or be observed in a control group.

Avner Raz, Lumenis President and Chief Executive Officer, stated, "Lumenis has provided the ophthalmic industry with innovative technology since 1970, when we introduced the world's "first" laser photocoagulator.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.